Print
Email

Email

RBC Trims Price Target on Apellis Pharmaceuticals to $24 From $25, Keeps Sector Perform Rating

Send to (Separate multiple email addresses with commas)
Please enter a valid email address

Your email address
Please enter a valid email address

Message (Optional)

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

Email

Your email has been sent.
Share
Share
RBC Trims Price Target on Apellis Pharmaceuticals to $24 From $25, Keeps Sector Perform Rating

Clicking a link will open a new window.
Default text size A
Larger text size A
Largest text size A

RBC Trims Price Target on Apellis Pharmaceuticals to $24 From $25, Keeps Sector Perform Rating

, MT Newswires - 7:29 AM ET 4/3/2025 default

07:29 AM EDT, 04/03/2025 (MT Newswires) -- Apellis Pharmaceuticals ( APLS ) has an average rating of overweight and mean price target of $43.15, according to analysts polled by FactSet.

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

© 1999-2025 Midnight Trader, Inc. All rights reserved.

RBC Trims Price Target on Apellis Pharmaceuticals to $24 From $25, Keeps Sector Perform Rating

Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "

Your e-mail has been sent.

Your e-mail has been sent.

Tennis-Djokovic motivated again after Miami run but keeping expectations low

Reuters - 11:57 PM ET 4/6/2025
Goldman Sachs raises odds of US recession to 45%

Reuters - 11:56 PM ET 4/6/2025
China's Horizon Robotics announces partnership with Volkswagen on advanced smart driving tech

Reuters - 11:44 PM ET 4/6/2025
NHL roundup: Caps' Alexander Ovechkin tops Gretzky's goals mark

Reuters - 11:33 PM ET 4/6/2025
Trump's tariff 'medicine' injects turmoil into global markets

Reuters - 11:28 PM ET 4/6/2025
Odds Of 2025 Recession Soar Above 60% On Crypto-Based Polymarket As Tariff Fears Pummel Markets, Bettors Root For Emergency Rate Cut

Benzinga - 11:25 PM ET 4/6/2025
China stocks sink on trade war fears; Hong Kong dives 9%

Reuters - 11:25 PM ET 4/6/2025
India's maintains 2025/26 growth projection despite US tariffs, official says

Reuters - 11:18 PM ET 4/6/2025

Content for this page, unless otherwise indicated with a Fidelity pyramid logo, is selected and published by Fidelity Interactive Content Services LLC ("FICS"), a Fidelity company. All Web pages published by FICS will contain this legend. FICS was established to present users with objective news, information, data and guidance on personal finance topics drawn from a diverse collection of sources including affiliated and non-affiliated financial services publications. Content selected and published by FICS drawn from affiliated Fidelity companies is labeled as such. FICS-selected content provided is not intended to provide tax, legal, insurance, or investment advice, and should not be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by any Fidelity entity or any third party. Quotes are delayed unless otherwise noted. FICS is owned by FMR LLC and is an affiliate of Fidelity Brokerage Services LLC. Terms of use for Third-Party Content and Research

These links are provided by Fidelity Brokerage Services LLC ("FBS") for educational and informational purposes only. FBS is responsible for the information contained in the links. FICS and FBS are separate but affiliated companies and FICS is not involved in the preparation or selection of these links, nor does it explicitly or implicitly endorse or approve information contained in the links.

Before investing, consider the funds' investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus or, if available, a summary prospectus containing this information. Read it carefully.